Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

Grau, S; Pozo, J C; Romá, E; Salavert, M; Barrueta, J A; Peral, C; Rodriguez, I; Rubio-Rodríguez, D; Rubio-Terrés, C

Grau, S; Pozo, J C; Romá, E; Salavert, M; Barrueta, J A; Peral, C; Rodriguez, I; Rubio-Rodríguez, D; Rubio-Terrés, C.

Afiliação

Grau S; Hospital del Mar (IMIM), Barcelona, Spain.
Pozo JC; Hospital Universitario Reina Sofía, Córdoba, Spain.
Romá E; Hospital Universitario Reina Sofía, Córdoba, Spain.
Salavert M; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Barrueta JA; Pfizer SLU, Alcobendas, Spain.
Peral C; Pfizer SLU, Alcobendas, Spain.
Rodriguez I; Trial Form Support, Madrid, Spain.
Rubio-Rodríguez D; Health Value, Madrid, Spain.
Rubio-Terrés C; Health Value, Madrid, Spain.

Clinicoecon Outcomes Res ; 7: 527-35, 2015.

Article em En | MEDLINE | ID: mdl-26508881

Palavras-chave

anidulafungin; candidemia; caspofungin; cost-effectiveness analysis; fluconazole; invasive candidiasis; micafungin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google